Users report migraines, eye pain and fatigue from experimental peptides, just as Health Secretary RFK Jr. moves to loosen access to them.
Recap by typeshit. Full story at The Washington Post on MSN.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A Facebook share offers general guidance on how people on GLP-1 medications might approach exercise. No details beyond the title are given.
SCOR separates trial tested GLP-1 drugs from untested peptides like BPC-157 and tracks the FDA's shifting compounding rules on 19 peptides since 2023.
Loading…